NCT04585724: Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

NCT04585724
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain
Additional Notes: Patients can have up to 10 brain metastases that are less than or equal to 3 cm in greatest dimension
Exclusions: Patients with brain metastases is greater than 3 cm; Patients with prior whole brain or craniospinal radiotherapy; Brain metastasis necessitating surgical or medical intervention
https://ClinicalTrials.gov/show/NCT04585724

Comments are closed.

Up ↑